Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8192)	1/5/1999 1:20:00 PM
From: JOEBT1	Read Replies (2) \| Respond to of 17367

George--I don't follow XOMA as closely as you and others do, but the article I saw on deaths in England cited 280 deaths out of 2800 cases. This is a 10% rather than 20% rate (which XOMA assumed for meningococcemia) thus the number of patients needed for statistical significance would increase. This may explain why the trial went well beyond its original enrollment plans. Can you or Caicito calculate the number of patients needed at the 10% rate.

To: aknahow who wrote (8192)	1/5/1999 5:07:00 PM
From: Tharos	Respond to of 17367

If there is a breakout I will probably add to my position. George, If there is a breakout I will definitely add to my position, but it currently represents a smaller percentage of my overall portfolio than you holding does in yours. Anyway, It makes sense technically to buy this particular breakout. It will have been at least 4 years since the stock saw that pricing. All of the weak hearts will have been shaken out by a combination of time vs. patience and by naysayers like RobertS. The stock will be poised for a run to the $16's based on the "double factor," and if we can get some euphoria behind it...who knows. Mean time, I like the concept, I like the technology, I like what they have targeted to treat, and in some regards I like the company. I am just as comfortable with my Xoma position as I am with my Motorola, Pfizer, and et.al. It's just riskier because there are no developed products. But even that is a misnomer because Xoma does have revenue-generating products, and if one were to look at Motorola's stock price over the last couple of years you would also see large price swings. I just add to my position as the opportunity avails itself. No different than some here with their Xoma positions. That I limit my Xoma position is related strictly to my portfolio management theories / diversification needs.